首页 | 本学科首页   官方微博 | 高级检索  
检索        

恩度静脉持续泵入与滴注联合含铂双药方案化疗治疗晚期非小细胞肺癌的疗效与安全性比较
引用本文:张梦茹,曹德东,戈伟.恩度静脉持续泵入与滴注联合含铂双药方案化疗治疗晚期非小细胞肺癌的疗效与安全性比较[J].实用肿瘤学杂志,2022,36(1):20-25.
作者姓名:张梦茹  曹德东  戈伟
作者单位:武汉大学人民医院肿瘤中心(武汉 430060)
基金项目:国家青年科学基金项目(编号:81700208)。
摘    要:目的 探讨恩度静脉持续泵入与滴注联合含铂双药方案一线化疗治疗晚期非小细胞肺癌(Non-small cell lung cancer,NSCLC)的临床疗效与安全性.方法 选取武汉大学人民医院2011年12月—2020年12月收治的100例病理分型为腺癌的晚期NSCLC患者作为研究对象,观察组为恩度静脉持续泵入(CIV)...

关 键 词:非小细胞肺癌  恩度  静脉持续泵入  静脉滴注  含铂双药化疗
收稿时间:2021-04-04

Comparison of efficacy and safety of Endostar intravenous continuous pumping and dripping combined with platinum-containing dual-drug regimen chemotherapy for the treatment of advanced non-small cell lung cancer
ZHANG Mengru,CAO Dedong,GE Wei.Comparison of efficacy and safety of Endostar intravenous continuous pumping and dripping combined with platinum-containing dual-drug regimen chemotherapy for the treatment of advanced non-small cell lung cancer[J].Journal of Practical Oncology,2022,36(1):20-25.
Authors:ZHANG Mengru  CAO Dedong  GE Wei
Institution:Center of Oncology,Renmin Hospital of Wuhan University,Wuhan 430060,China
Abstract:Objective The objective of this study was to investigate the clinical efficacy and safety of intravenous continuous pumping and infusion of Endostar combined with platinum-containing dual-drug regimen as first-line chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC).Methods A total of 100 advanced NSCLC patients with pathological classification of adenocarcinoma who were admitted to Renmin Hospital of Wuhan University from December 2011 to December 2020 were selected as the research objects.The observation group was the CIV group,a total of 50 patients in the group were treated with Endostar intravenous continuous pumping combined with pemetrexed and nedaplatin.The control group was the DIV group,with the other 50 patients treated with Endostar intravenous infusion combined with pemetrexed and nedaplatin chemotherapy regimen.The overall response rate(ORR),disease control rate(DCR),and the occurrence of toxic and side effects between the two groups of patients were compared.Results The ORR of the observation group was 38.0%,which was higher than that of the control group(18.0%).The difference was statistically significant(P=0.026).The DCR of the observation group was 92.0%,which was higher than that of the control group(74.0%),and the difference was statistically significant(P=0.017).The occurrence of toxic and side effects was not statistically significant(P>0.05).The results of Cox regression analysis showed that the method of administration was not a factor influencing progression-free survival(PFS)in patients with advanced NSCLC(P=0.340),and radiotherapy was an independent factor affecting PFS in patients with advanced NSCLC(P<0.05).The PFS of patients who received radiotherapy was longer than that of patients who did not receive radiotherapy(HR=1.708,95%CI1.041~2.801).Conclusion The ORR and DCR of patients with advanced NSCLC treated with continuous intravenous pumping combined with first-line chemotherapy with platinum-containing two-drug regimen were higher than those treated with intravenous infusion,without aggravating related toxic and side effects.Among them,the risk of tumor progression in patients receiving radiotherapy was lower than that in patients not receiving radiotherapy.
Keywords:Non-small cell lung cancer  Endostar  Continuous intravenous pumping  Intravenous infusion  Platinum-containing dual-drug chemotherapy
本文献已被 维普 等数据库收录!
点击此处可从《实用肿瘤学杂志》浏览原始摘要信息
点击此处可从《实用肿瘤学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号